10-Q: Allied Corp. Reports Q1 2025 Results with Narrowed Losses Amidst Ongoing Financial Challenges

Allied Corp. reported a net loss of $780,290 for the quarter ended November 30, 2024, a slight improvement compared to the same period last year, while facing continued going concern challenges.

Summary

• Allied Corp. reported a net loss of $780,290 for the three months ended November 30, 2024, compared to a net loss of $836,673 for the same period in 2023.
• The company's revenue increased to $27,669 from $19,039 year-over-year.
• Gross margin decreased to $13,611 from $17,036 year-over-year.
• Operating expenses decreased to $622,429 from $809,163 year-over-year, primarily due to a reduction in consulting fees.
• The company's working capital deficit was $8,874,738 as of November 30, 2024.
• Allied Corp. is facing going concern issues due to its accumulated deficit of $50,364,810 and minimal revenue generation.
• The company's ability to continue operations is dependent on raising sufficient financing.
• The company has a loan payable of $2,813,600 due on demand.
• The company has secured convertible notes payable of $3,774,891 with accrued interest of $1,196,843.

Sentiment

Score: 3

Explanation: The document highlights some positive aspects such as increased revenue and reduced losses, but the significant working capital deficit, going concern issues, and ongoing litigation create a negative outlook. The company's reliance on future financing and the uncertainty surrounding its ability to continue operations contribute to a low sentiment score.

Positives

• The company's net loss decreased compared to the same period last year.
• Revenue increased year-over-year.
• Operating expenses decreased year-over-year.
• The company secured additional equity financing during the quarter.

Negatives

• The company has a significant working capital deficit of $8,874,738.
• The company is facing going concern issues due to its accumulated deficit and minimal revenue.
• The company has a loan payable of $2,813,600 due on demand.
• The company has secured convertible notes payable of $3,774,891 with accrued interest of $1,196,843.
• The company's gross margin decreased year-over-year.

Risks

• The company's ability to continue as a going concern is dependent on raising sufficient financing.
• The company's operations are subject to the risks associated with the cannabis industry, including regulatory changes.
• The company has a significant working capital deficit and may not be able to meet its financial obligations.
• The company is involved in ongoing litigation regarding a building in Nevada.
• The company's loans payable are due on demand.

Future Outlook

The company's ability to continue operations is dependent on raising sufficient financing to develop a profitable business. Management intends on financing its operations and future development activities largely from the sale of equity securities and debt financing with some additional funding from other traditional financing sources, including related party loans until such time that funds provided by future planned operations are sufficient to fund working capital requirements.

Management Comments

• The management team believes that having control over our supply chain should enable us to provide a consistent, rolling-harvest supply to the global cannabis community.
• Our management team believes that having control over our supply chain should enable us to provide a consistent, rolling-harvest supply to the global cannabis community.
• The Company is dedicated to meeting the evolving needs of patients and healthcare professionals with its high-quality medical cannabis products, underpinned by rigorous quality standards and ethical cultivation & processing practices.

Industry Context

The company operates in the medical cannabis industry, which is subject to evolving regulations and market conditions. The company's focus on low-cost production in Colombia is a strategy to gain a competitive advantage in the global market. The company is also focused on developing therapeutic products for specific medical conditions.

Comparison to Industry Standards

• The company's stated production cost of $0.05 $0.075 per gram of raw flower in Colombia is significantly lower than the average cost of $1.00 $2.00 per gram in North America, suggesting a potential competitive advantage.
• The company's focus on vertically integrated supply chain is a common strategy in the cannabis industry to control costs and ensure consistent supply.
• The company's focus on medical cannabis and specific therapeutic applications aligns with the growing trend of using cannabis for medical purposes.
• The company's financial results, including the net loss and working capital deficit, are not uncommon for early-stage cannabis companies, but the going concern issue is a significant concern.

Management Changes

Legal Proceedings

• The company is involved in litigation in Nevada regarding ownership of a building after the insolvency of Fiore Cannabis.

Related Party Transactions

• The company settled $214,782 in payables by issuing 1,073,912 common shares to related parties.
• The company entered into an agreement with certain related parties to settle outstanding payables related to prior management and consulting services.
• The company received short-term loans from its CBDO and one of its directors.
• The company shares certain administrative resources with entities related by common management and directors.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance and the going concern issues.
• Employees are impacted by the company's financial stability and ability to continue operations.
• Customers are impacted by the company's ability to provide consistent supply of cannabis products.
• Creditors are impacted by the company's ability to meet its financial obligations.

Next Steps

• The company needs to secure additional financing to continue operations.
• The company needs to resolve the ongoing litigation regarding the Nevada building.
• The company needs to continue to develop its cannabis products and expand its market reach.
• The company needs to address the material weakness in internal control over financial reporting.

Key Dates

Keywords

cannabis, medical cannabis, financial results, going concern, equity financing, convertible notes, working capital, net loss, revenue, operating expenses, Colombia, stock options